Wednesday, 27 May 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 27 May 2026
News

Sanofi ends 100-year drought

Posted 27 May 2026 AM

Sanofi has successfully brought its type 1 diabetes (T1D) disease-modifying therapy Tzield to Australia, marking the biggest development in the field since the discovery of insulin more than a century ago, with the company actively pursuing reimbursement for the drug.

Last week the TGA approved Tzield to delay the onset of Stage 3 T1D in adult and paediatric patients aged eight years and older with Stage 2 T1D.

To see the whole article, please login

Popular

Gladys takes health sector role
Country Leader back after Gap Year
Dark Horse climbs Innovation Index
Ex-Aussie Country Boss collects prize
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (16)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (3)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home